Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium/Formoterol via Discair in COPD
NCT02988869Phase 4Completed
- Sponsor
- Neutec Group
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tiotropium and formoterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Neutec Group. Primary endpoints: Mean max change from baseline in FEV1 at 24 hours, Mean % change from baseline in FEV1 at 24 hours and 4 more. Started Aug 2016; status: completed.
02
Drugs
tiotropiumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02988869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988869.